TY - JOUR T1 - r肺纤维化量表(PF):一种简单的、可视的工具评估健康相关的生活质量的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00917 -2021欧元SP - 2100917 AU Scallan Ciaran AU -链,劳伦AU -海耶斯,詹妮弗盟——Kadura苏哈AU -柯林斯,布丽姬特盟- Ho,劳伦斯AU -位咨询专家,卡罗琳AU - Canestaro,将非盟-科尔布,Martin AU - Raghu, Ganesh Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/05/28/13993003.00917-2021.abstract N2 -基本原理特发性肺纤维化(IPF)患者的健康相关生活质量(HRQoL)受损。已经开发了几种工具来客观地评估这一人群的HRQoL，但没有一种工具用于常规临床实践。目的:开发一种快速、特异的工具，可用于临床常规就诊的IPF患者。方法编制一套新颖、简单的5项数字评分量表(NRS)，并与另外两种已有验证的量表进行比较。在ILD中心管理的100名连续IPF患者中，除了肺功能和6分钟步行测试外，还被招募完成R-Scale-PF、Kings简要间质性肺病问卷(K-BILD)和EuroQol 5维5级问卷(eq - 5d - 5l)。测量和主要结果所有100例患者成功完成了3种HRQoL工具，其中53例在随访时再次完成。内部一致性高(Cronbach’s α 0.825)，最低限度限制。与K-BILD (r=−0.713)和EQ-5D-5 L (r=−0.665)相比，r - scale - pf的并行效度为中至高。同时效度中等的生理指标(强迫肺活量，r=−0.307,6分钟步行距离，r=−0.383)。R-Scale-PF在比较疾病严重程度各阶段的评分时，证明了良好的组效度。结论R-Scale-PF与K-BILD、eq - 5d - 5l有良好的相关性。 It is hoped that this novel simple NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose. ER -